Compare · NVO vs ONCO
NVO vs ONCO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Onconetix Inc. (ONCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONCO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 60460.7x ONCO ($2.9M).
- Over the past year, NVO is down 28.6% and ONCO is down 99.7% - NVO leads by 71.1 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for ONCO).
- NVO has more recent analyst coverage (25 ratings vs 0 for ONCO).
- Company
- Novo Nordisk A/S
- Onconetix Inc.
- Price
- $38.82-1.05%
- $0.48-11.96%
- Market cap
- $173.66B
- $2.9M
- 1M return
- -10.14%
- -28.02%
- 1Y return
- -28.57%
- -99.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest ONCO
- SEC Form DEF 14A filed by Onconetix Inc.
- SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
- SEC Form PRE 14A filed by Onconetix Inc.
- CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
- SEC Form DEFA14A filed by Onconetix Inc.
- Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 425 filed by Onconetix Inc.
- SEC Form 424B3 filed by Onconetix Inc.
- SEC Form EFFECT filed by Onconetix Inc.
- SEC Form 425 filed by Onconetix Inc.